ReviewJournal of neuroinflammation2019
Molecular biomarkers in multiple sclerosis.
Review in Journal of neuroinflammation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05451069 (Combined Neurofilament Light Chain ,Chitinase-3 Like-1 Protein Levels and Tolerogenic Plasmacytoid Dendritic Cells in Defining Disease Course in Multiple Sclerosis Patients), which is not on this map. Cited by 116 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Combined Neurofilament Light Chain ,Chitinase-3 Like-1 Protein Levels and Tolerogenic Plasmacytoid Dendritic Cells in Defining Disease Course in Multiple Sclerosis Patients
Who cites it
116 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Cerebrospinal fluid inflammatory biomarkers for disease progression in Alzheimer's disease and multiple sclerosis: a systematic review.Frontiers in immunology · 2023Pooled it
- Tear Biomarkers in Alzheimer's and Parkinson's Diseases, and Multiple Sclerosis: Implications for Diagnosis (Systematic Review).International journal of molecular sciences · 2022Pooled it
- Role of Chitinase 3-like 1 as a Biomarker in Multiple Sclerosis: A Systematic Review and Meta-analysis.Neurology(R) neuroimmunology & neuroinflammation · 2022Pooled it
- Serum neurofilament indicates that DBS surgery can cause neuronal damage whereas stimulation itself does not.Scientific reports · 2022Trial
- From measurement to biomarker trajectories: platform-agnostic Z score analysis of serum NfL and GFAP in ocrelizumab-treated multiple sclerosis.Journal of neurology · 2026Article
- Neurofilament light chain and glial fibrillary acidic protein as biomarkers of peripheral nervous system involvement in multiple sclerosis: diagnostic and prognostic evaluation.BMC neurology · 2026Article
- CSF Proteins Associated With Neuroaxonal Damage in Early Active Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- MS360°: a conceptual digital-first, data-driven hybrid care framework for personalised multiple sclerosis management.NPJ digital medicine · 2026Review
- MALDI-TOF mass spectrometry imaging of sulfatide lipid expression in the CNS of mice with experimental autoimmune encephalomyelitis.Scientific reports · 2026Article
- Plasmaphosphorylated tau as biomarkers for multiple sclerosis diagnosis, subtyping, and prognosis.Brain communications · 2026Article
- CHI3L1 and CXCL13 Levels of Serum and CSF in Treatment-Naïve Multiple Sclerosis: Associations with Disease Activity.Noro psikiyatri arsivi · 2026Article
- Article
- Spheres of uncertainty: A phenomenological inquiry into healthcare practice surrounding the care for people with relapsing-remitting multiple sclerosis.Qualitative research in medicine & healthcare · 2025Article
- Clinical characteristics and treatment of patients with overlapping MOG and anti-NMDAR encephalitis.BMC neurology · 2025Article
- Chitosan (Nano)formulations as Therapeutic Tools for Neurodegenerative Diseases: A Comprehensive Review.Polymers · 2025Review
- Imaging of Cerebral Iron as an Emerging Marker for Brain Aging, Neurodegeneration, and Cerebrovascular Diseases.Brain sciences · 2025Review
- Sysmex XN-Based Evaluation of the Diagnostic Performance of High-Fluorescent Cells From CSF as a Supportive Diagnostic Criterion in Neurological Diseases.International journal of laboratory hematology · 2025Article
- FABP7 is increased in progressive multiple sclerosis and induces a pro-inflammatory phenotype in monocytes through a glycolytic switch.Nature communications · 2025Article
- Neurodegenerative Biomarkers in Multiple Sclerosis: At the Interface Between Research and Clinical Practice.Diagnostics (Basel, Switzerland) · 2025Review
- Novel serum biomarker associations with 7 Tesla MRI-defined cortical lesions, leptomeningeal enhancement, and deep gray matter volume in early multiple sclerosis.Scientific reports · 2025Article
56 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is an inflammatory-neurodegenerative disease of the central nervous system presenting with significant inter- and intraindividual heterogeneity. However, the application of clinical and imaging biomarkers is currently not able to allow individual characterization and prediction. Complementary, molecular biomarkers which are easily quantifiable come from the areas of immunology and neurobiology due to the causal pathomechanisms and can excellently complement other disease characteristics. Only a few molecular biomarkers have so far been routinely used in clinical practice as their validation and transfer take a long time. This review describes the characteristics that an ideal MS biomarker should have and the challenges of establishing new biomarkers. In addition, clinically relevant and promising biomarkers from the blood and cerebrospinal fluid are presented which are useful for MS diagnosis and prognosis as well as for the assessment of therapy response and side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.